Sector pending / Pharmaceutical PreparationsUpdated 2026-05-10 22:07 UTC

FRA/PHE stock hub

FRA/PHE has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/PHEis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

311.1M

Frankfurt Stock Exchange

Market data

Price

Recent price action with selectable time range.

FRA/PHEFRA/PHE

—

Loading chart…

In the news

Latest news · FRA/PHE

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/E11.6

P25 n/aP50 n/aP75 n/a

ROE25.9

P25 n/aP50 n/aP75 n/a

ROIC16

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/PHE market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

211

Groups with data

Currency

USD

Showing 211 of 211 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Canada
Country code	DE
Employees	5
Employees Change	-1%
Employees Change Percent	-16.67
Enterprise value	EUR 305.9M
Exchange	Frankfurt Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Pharmaceutical Preparations
Last refreshed	2026-05-10
Market cap	EUR 311.1M
Price	EUR 12.2
Price currency	EUR
Rev Per Employee	8,835,532x
Sic	2834
Symbol	fra/PHE
Website	https://www.cipherpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	8.61%
EV Earnings	11.43x
EV/EBIT	17.55x
EV/EBITDA	12.92x
EV/FCF	11.76x
EV/Sales	6.93x
FCF yield	8.36%
P/B ratio	2.7x
P/E ratio	11.62x
P/S ratio	7.04x
PE Ratio10 Y	11.09x
PE Ratio3 Y	12.04x
PE Ratio5 Y	9.32x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	39.49%
EBITDA Margin	53.1%
FCF margin	58.9%
Gross margin	81.63%
Gross Profit	EUR 36.1M
Gross Profit Growth	46.25%
Gross Profit Growth Q	12.66%
Gross Profit Growth3 Y	36.64%
Gross Profit Growth5 Y	18.19%
Net Income	EUR 26.8M
Net Income Growth	233.85%
Net Income Growth Q	134.87%
Net Income Growth3 Y	4.42%
Net Income Growth5 Y	56.89%
Pretax Margin	39.71%
Profit Margin	60.6%
Profit Per Employee	EUR 5.4M
ROA	7.95
Roa5y	9.33
ROCE	15.13
ROE	25.94
Roe5y	27.63
ROIC	16.03
Roic5y	26.36

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	10.02%
Cagr15y	22.91%
Cagr1y	34.09%
Cagr3y	77.52%
Cagr5y	66.56%
EPS Growth	227.7
EPS Growth Q	140
EPS Growth3 Y	4.17
EPS Growth5 Y	58.21
FCF Growth Q	7.18%
FCF Growth3 Y	30.96%
FCF Growth5 Y	23.09%
OCF Growth	40.77%
OCF Growth Q	7.16%
OCF Growth10 Y	15.85%
OCF Growth3 Y	30.74%
OCF Growth5 Y	23.09%
Revenue Growth	28.91x
Revenue Growth Q	4.04x
Revenue Growth3 Y	36.24x
Revenue Growth5 Y	19.21x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.32
Assets	EUR 132.9M
Cash	EUR 5.6M
Current Assets	EUR 21.6M
Current Liabilities	EUR 17.3M
Debt	EUR 371,204
Debt EBITDA	EUR 0.02
Debt Equity	EUR 0
Debt FCF	EUR 0.01
Equity	EUR 115.1M
Interest Coverage	26.96
Liabilities	EUR 17.8M
Long Term Assets	EUR 111.3M
Long Term Liabilities	EUR 536,981
Net Cash	EUR 5.2M
Net Cash By Market Cap	EUR 1.67
Net Debt EBITDA	EUR -0.22
Net Debt Equity	EUR -0.05
Net Debt FCF	EUR -0.2
Tangible Book Value	EUR 38.6M
Tangible Book Value Per Share	EUR 1.5

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.25
Inventory Turnover	1.36
Net Working Capital	EUR -881,177
Quick ratio	0.79
Working Capital	EUR 4.5M
Working Capital Turnover	EUR 3.19

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.65%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	159.8%
1Y total return	34.07%
200-day SMA	9.29
3Y total return	459.63%
50-day SMA	10.49
50-day SMA vs 200-day SMA	50over200
5Y total return	1,181.51%
All Time High	13.45
All Time High Change	-9.29%
All Time High Date	2014-12-23
All Time Low	0.17
All Time Low Change	7,076.47%
All Time Low Date	2009-01-02
ATR	0.47
Ch YTD	32.61
High	12.2
High52	12.2
High52 Date	2026-05-08
High52ch	0%
Low	10.7
Low52	7
Low52 Date	2026-02-02
Low52ch	74.29%
Ma50ch	16.33%
Price vs 200-day SMA	31.37%
RSI	62.69
RSI Monthly	66.18
RSI Weekly	67.01
Sharpe ratio	0.73x
Sortino ratio	1.38
Total Return	-0.65%
Tr YTD	32.61
Tr15y	2,106.15%
Tr1m	5.17%
Tr1w	7.97%
Tr3m	53.46%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 17.4M
Operating Income Growth	181.7
Operating Income Growth Q	126.2
Operating Income Growth3 Y	24.06
Operating Income Growth5 Y	11.06
Operating margin	39.49

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	14,923,970%
Net Borrowing	-34,179,652.3
Shares Insiders	3.55%
Shares Institutions	1.48%
Shares Qo Q	-1.61%
Shares Yo Y	0.65%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR 24.5M
Average Volume	25.05x
Bv Per Share	4.48
CAPEX	EUR -23,417
Ch10y	159.8
Ch15y	2,106.1
Ch1m	5.17
Ch1w	7.97
Ch1y	34.07
Ch3m	53.46
Ch3y	459.6
Ch5y	1,181.5
Ch6m	48.78
Change	10.91%
Change From Open	14.02
Close	11
Days Gap	-2.73
Depreciation Amortization	5,878,072.6
Dollar Volume	6,112.2
Earnings Date	2026-05-07
EBIT	EUR 17.4M
EBITDA	EUR 23.5M
EPS	EUR 1.03
F Score	5
FCF	EUR 26M
FCF EV Yield	8.51x
Financing CF	-39,436,131
Fiscal Year End	December
Founded	2,000
Goodwill	14,794,393
Graham Number	10.32801
Graham Upside	-15.34
Income Tax	EUR -9.2M
Investing CF	-486,555
Is Primary Listing	0
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Lynch Fair Value	EUR 26.25
Lynch Upside	115.2
Ma150	9.34
Ma150ch	30.63%
Ma20	11.3
Ma20ch	8.01%
Net CF	-13,521,207
Open	10.7
P FCF Ratio	11.96
P OCF Ratio	11.94
Position In Range	100
Ppne	405,325.8
Price Date	2026-05-08
Price EBITDA	EUR 13.26
Ptbv Ratio	8.07
Relative Volume	2,000x
Revenue	44,177,660x
SBC By Revenue	3.53x
Share Based Comp	1,559,405
Tax By Revenue	-20.89x
Tr6m	48.78%
Volume	501

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/PHE pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/PHE stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/PHE?

Insider, institutional, and short-interest positioning.

Institutional ownership

+1.5%

Share of float held by funds and institutions

Insider ownership

+3.5%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+0.6%

Negative means the company is buying back shares.

Technical

FRA/PHE momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

62.7

Neutral momentum band

Price vs 200-day MA

+31.4%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

0.73

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/PHE

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/PHE stock rating?

fra/PHE is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/PHE analysis?

The full report lives at /stocks/fra/PHE/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/PHE?

The latest report frames fra/PHE around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/PHE page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.